6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Clinical News

Baxter reports Phase III hemophilia data for BAX 326

Baxter International Inc. (NYSE:BAX) said twice-weekly prophylactic BAX 326 met the co-primary endpoint of annualized bleed rate in the Phase III portion of an international Phase...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >